Abstract |
The trial CICL670AUS04 was a single-arm, open-label study of the cardiac efficacy of 18 months of deferasirox monotherapy [1]. Cardiac response in this study was related to the degree of liver siderosis. Patients with mild to moderate liver siderosis improved their cardiac T2* while more severely siderotic patients did not, regardless of initial cardiac iron burden. In this letter, we report 2-year data in those patients who completed a 6-month extension phase (N 5 10). Cardiac and liver iron improved steadily during the 24-month period, with final cardiac T2* and LIC improving 37% and 27%, respectively, in this cohort. Serum ferritin and LVEF were not statistically different at anytime-point. When the extension phase (18-24 months) was considered in isolation, serum ferritin, liver iron concentration, and left ventricular ejection fraction were nearly identical to 18 month results. Despite this, cardiac T2* continued to trend higher, increasing 12.7% from 9.5 ms to 10.7 ms (P 5 0.06). Thus defersirox continued to demonstrate cardiac efficacy in patients with mild to moderate hepatic siderosis throughout 2 years of therapy.
|
Authors | John C Wood, Tara Glynos, Alexis Thompson, Patricia Giardina, Paul Harmatz, Barinder P Kang, Carole Paley, Thomas D Coates |
Journal | American journal of hematology
(Am J Hematol)
Vol. 85
Issue 10
Pg. 818-9
(Oct 2010)
ISSN: 1096-8652 [Electronic] United States |
PMID | 20799360
(Publication Type: Clinical Trial, Letter, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Benzoates
- Iron Chelating Agents
- Triazoles
- Ferritins
- Deferasirox
|
Topics |
- Benzoates
(therapeutic use)
- Cardiomyopathies
(drug therapy, etiology)
- Chelation Therapy
- Deferasirox
- Ferritins
(analysis)
- Follow-Up Studies
- Humans
- Iron Chelating Agents
(therapeutic use)
- Liver Diseases
(drug therapy, etiology)
- Siderosis
(drug therapy, etiology)
- Stroke Volume
- Transfusion Reaction
- Treatment Outcome
- Triazoles
(therapeutic use)
- beta-Thalassemia
(complications)
|